Merck Sharp & Dohme Corp. vs. GlaxoSmithKline Biologicals SA
Explore the PTAB proceeding IPR2018-01236 filed by Merck Sharp & Dohme Corp. on 2018-06-11. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2018-01236
Filing Date
2018-06-11
Accorded Filing Date
2018-06-11
Institution Decision Date
2018-12-18
Last Modified Date
2022-05-10
Proceeding Type
IPR
Termination Date
2019-06-12
Trial Status
Terminated-Settled
Parties & Counsel
Petitioner
Merck Sharp & Dohme Corp.
Represented By
Anthony InsognaPatent Owner / Respondent
GlaxoSmithKline Biologicals SA
Represented By
Charles LipseyPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
1 Total
Proceeding Status
Terminated-Settled
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 36689 | Nora Stein | +1 484-949-5801 |
| 40820 | Robert Smith | +1 980-219-9608 |
| 45582 | John Young | +1 919-483-8160 |
| 45941 | Eric Kron | +1 919-483-8961 |
| 47115 | J. Strickland | +1 919-483-9024 |
| 48708 | Joseph Schuller | +1 202-617-7187 |
| 51491 | Alice Bradney | +1 919-450-8851 |
| 58542 | William Long | +1 484-919-7863 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 8,753,645 Asserted | Asserted Patent | View Official Patent → |
| ๐ฌ๐ง United Kingdom | GB 1003922 | United Kingdom Counterpart | View Official Patent → |
| ๐ฌ๐ง United Kingdom | GB 201003922 D0 | United Kingdom Counterpart | View Official Patent → |
| ๐ PCT International (WIPO) | WO 2011110531 A2 | PCT World Application | View Official Patent → |
| ๐บ๐ธ United States | US 9,265,840 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 9,265,839 B2 | US Continuation / Sibling | View Official Patent → |
Merck Sharp & Dohme Corp. v. GlaxoSmithKline Biologicals SA
Merck Sharp & Dohme Corp. v. GlaxoSmithKline Biologicals SA
Merck Sharp & Dohme Corp. v. GlaxoSmithKline Biologicals SA
Standard Essential Patent (SEP) & FRAND Intelligence
5G SEP โข ETSI Declared High-Probability SEP ActionEssential standard specifications, SSO declaration status, and FRAND antitrust defense evaluation
Injunction Restrictions & FRAND Defense Leverage (CJEU Huawei v. ZTE Framework)
Permanent Injunction RestrictedAsserted by recognized SEP declarant. Under the CJEU Huawei v. ZTE test, injunctions are barred if the defendant qualifies as a willing licensee.